 BSEM, a rising MedTech firm, just received another price increase from Zack's Small Cap Research to $23.25!A study published in a peer-reviewed journal finds BioStem's products offer overall better treatment efficiency and greater efficiency in general wound closure! Regenerative medicine is one of the most exciting arenas in medicine. BioStem Technologies (BSEM) is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts for regenerative therapies. The company recently had exciting news revealing that an article has validated its proprietary processing method and its placental allograft products have been published in the international, peer-reviewed journal, Health Science Reports. A study's primary objective was to evaluate and compare the effectiveness of two wound care products for managing diabetic foot ulcers, including BioStem's AmnioWrap2® (RE-AC), processed using the BioREtain® method, and (L-AC) processed through a more ablative method used by a leading competitor in the industry. The study found that RE-AC products required fewer applications, suggesting greater efficiency in managing wounds, and that they offered overall better efficiency! Jason Matuszewski, BioStem's Chief Executive Officer, said, "This complete analysis of wound care products not only provides validation of BioStem's proprietary BioREtain method, it is a testament to the clinical utility of our allografts. Current standard of care (SOC) methods are ineffective for many patients, with up to 70% of diabetic foot ulcers (DFU) not achieving healing even after 20 weeks of treatment. Our products lead to cost savings, enhanced patient comfort, and improved compliance with treatment protocols." Discover more about how BSEM's products have advantages over other wound care management products on the market today and why Zack's Small Cap Research has a price target of $23.25!This message is a PAID ADVERTISEMENT for BioStem Technologies, Inc. (BSEM) from Sideways Frequency. StockEarnings, Inc receives a fixed fee of $3000 for this email. Other than the compensation received for this advertisement sent to subscribers, StockEarnings and its principals are not affiliated with either BioStem Technologies, Inc. (BSEM) or Sideways Frequency. StockEarnings and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither StockEarnings nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from StockEarnings to buy or sell any security. StockEarnings has not evaluated the accuracy of any claims made in this advertisement. StockEarnings recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results. Please see the disclaimer regarding BioStem Technologies, Inc. (BSEM) on Huge Alerts website for additional information about the relationship between Sideways Frequency and BioStem Technologies, Inc. (BSEM). Your privacy is very important to us, if you wish to be excluded from future notices, do not reply to this message. Instead, please click Unsubscribe. StockEarnings, Inc |
No comments:
Post a Comment